• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of seventh TNM and eighth TNM staging system in stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy.

作者信息

Yılmaz Ufuk, Özdemir Özer, Yılmaz Ülkü

机构信息

Department of Pulmonology, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey.

Department of Pulmonology, Kemalpaşa State Hospital, İzmir, Turkey.

出版信息

Curr Probl Cancer. 2019 Feb;43(1):33-42. doi: 10.1016/j.currproblcancer.2018.04.002. Epub 2018 Apr 30.

DOI:10.1016/j.currproblcancer.2018.04.002
PMID:29804944
Abstract
摘要

相似文献

1
Comparison of seventh TNM and eighth TNM staging system in stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy.同步放化疗治疗的Ⅲ期非小细胞肺癌患者中第七版与第八版TNM分期系统的比较
Curr Probl Cancer. 2019 Feb;43(1):33-42. doi: 10.1016/j.currproblcancer.2018.04.002. Epub 2018 Apr 30.
2
Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.不同给药途径的重组人血管内皮抑制素联合同期放化疗治疗局部晚期非小细胞肺癌的疗效和安全性：两项Ⅱ期临床试验的随访结果更新。
Thorac Cancer. 2020 Apr;11(4):898-906. doi: 10.1111/1759-7714.13333. Epub 2020 Feb 18.
3
Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.不可切除的 III 期非小细胞肺癌患者的治疗模式和总生存情况。
Future Oncol. 2019 Oct;15(29):3381-3393. doi: 10.2217/fon-2019-0282. Epub 2019 Sep 23.
4
Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.在 durvalumab 获批前局部晚期非小细胞肺癌患者同步放化疗的现状和进展。
Thorac Cancer. 2020 Apr;11(4):1005-1014. doi: 10.1111/1759-7714.13357. Epub 2020 Feb 14.
5
Prognostic Factor and Clinical Outcome in Stage III Non-Small Cell Lung Cancer: A Study Based on Real-World Clinical Data in the Korean Population.基于韩国人群真实世界临床数据的 III 期非小细胞肺癌预后因素和临床结局研究。
Cancer Res Treat. 2021 Oct;53(4):1033-1041. doi: 10.4143/crt.2020.1350. Epub 2021 Feb 16.
6
Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy.根治性放化疗治疗 IIIB 期老年非小细胞肺癌患者时，预处理格拉斯哥预后评分的预后价值。
J Geriatr Oncol. 2019 Jul;10(4):567-572. doi: 10.1016/j.jgo.2018.10.014. Epub 2018 Oct 26.
7
Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.纳入分子预后分类器可改善常规非小细胞肺癌分期。
J Thorac Oncol. 2019 Jul;14(7):1223-1232. doi: 10.1016/j.jtho.2019.03.015. Epub 2019 Apr 5.
8
Impact of histology on patterns of failure and clinical outcomes in patients treated with definitive chemoradiotherapy for locally advanced non-small cell lung cancer.组织学对接受根治性放化疗的局部晚期非小细胞肺癌患者失败模式和临床结局的影响。
Int J Clin Oncol. 2020 Feb;25(2):274-281. doi: 10.1007/s10147-019-01566-z. Epub 2019 Oct 30.
9
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.优化接受放化疗联合或不联合手术的可切除性边缘的IIIA期非小细胞肺癌患者的生存率
Clin Lung Cancer. 2016 Nov;17(6):550-557. doi: 10.1016/j.cllc.2016.05.013. Epub 2016 Jun 8.
10
Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy.新的第八版非小细胞肺癌TNM分期系统在接受根治性同步放化疗治疗中的应用。
Radiat Oncol. 2017 Jul 21;12(1):122. doi: 10.1186/s13014-017-0848-2.

引用本文的文献

1
Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.了解魁北克一个单一中心不可切除 III 期非小细胞肺癌患者的临床实践和生存结局。
Curr Oncol. 2020 Oct;27(5):e459-e466. doi: 10.3747/co.27.6241. Epub 2020 Oct 1.
2
Prognostic value of the common tumour-infiltrating lymphocyte subtypes for patients with non-small cell lung cancer: A meta-analysis.常见肿瘤浸润淋巴细胞亚型对非小细胞肺癌患者预后的价值：一项荟萃分析。
PLoS One. 2020 Nov 10;15(11):e0242173. doi: 10.1371/journal.pone.0242173. eCollection 2020.
3
Comment on an external validation of the 8th edition of the TNM classification for lung cancer staging in patients treated with chemoradiation.
关于接受放化疗的肺癌患者第八版TNM分期分类的外部验证的评论
Ann Transl Med. 2019 Jul;7(Suppl 3):S101. doi: 10.21037/atm.2019.04.81.